FDA
- Marketing authorisation holder: MEDPOINTE PHARM HLC
- Status: approved
Hexafluorenium Bromide (hexafluronium) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
MEDPOINTE PHARM HLC holds the US marketing authorisation.